AbbVie Inc.ABBVNYSE
LOADING
|||
R&D Expense Growth Recovery in Progress
Trending higher, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
6.86%
↓ 54% below average
Average (39q)
15.06%
Historical baseline
Range
High:413.61%
Low:-78.75%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 6.86% |
| Q2 2025 | 1.60% |
| Q1 2025 | -69.49% |
| Q4 2024 | 218.03% |
| Q3 2024 | 9.34% |
| Q2 2024 | 0.46% |
| Q1 2024 | -12.22% |
| Q4 2023 | 28.21% |
| Q3 2023 | -0.58% |
| Q2 2023 | -24.39% |
| Q1 2023 | 12.74% |
| Q4 2022 | 25.96% |
| Q3 2022 | -14.06% |
| Q2 2022 | 14.37% |
| Q1 2022 | -26.43% |
| Q4 2021 | 8.19% |
| Q3 2021 | 8.64% |
| Q2 2021 | 2.54% |
| Q1 2021 | -15.43% |
| Q4 2020 | 28.37% |
| Q3 2020 | -29.94% |
| Q2 2020 | 76.58% |
| Q1 2020 | -17.97% |
| Q4 2019 | -26.43% |
| Q3 2019 | 65.34% |
| Q2 2019 | -4.29% |
| Q1 2019 | -78.75% |
| Q4 2018 | 413.61% |
| Q3 2018 | 0.08% |
| Q2 2018 | 6.27% |
| Q1 2018 | -11.27% |
| Q4 2017 | 14.73% |
| Q3 2017 | -0.08% |
| Q2 2017 | 7.75% |
| Q1 2017 | -4.62% |
| Q4 2016 | 7.59% |
| Q3 2016 | -1.60% |
| Q2 2016 | 18.82% |
| Q1 2016 | -12.00% |
| Q4 2015 | -24.19% |